SCHEMBL11943925

SCHEMBL11943925

CCCCCC(C)Oc1c(N2CCN(S(=O)(=O)c3ccc(F)cc3)CC2)cnn(-c2ccccc2)c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.51
▸ POLB P06746 2/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ PPARG P37231 1/20 0.51
▸ NCOA2 Q15596 1/20 0.51
▸ NCOA1 Q15788 1/20 0.51
▸ NPSR1 Q6W5P4 1/20 0.51
▸ NCOA3 Q9Y6Q9 1/20 0.51
▸ MAPT P10636 1/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ USP2 O75604 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ HPGD P15428 1/20 0.45
▸ DCTPP1 Q9H773 1/20 0.43
▸ PKM P14618 3/20 0.40
▸ LMNA P02545 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11945050 0.87 MAPT (0.51) ALDH1A1POLBNPSR1MAPTSMN1; SMN2
SCHEMBL11943886 0.85 MAPT (0.46) ALDH1A1POLBMAPTSMN1; SMN2L3MBTL1
SCHEMBL11945042 0.84 MAPT (0.53) ALDH1A1POLBCYP2C19MAPTSMN1; SMN2
SCHEMBL11945005 0.84 MAPT (0.45) ALDH1A1POLBMAPTSMN1; SMN2L3MBTL1
SCHEMBL11945086 0.82 MAPT (0.54) ALDH1A1POLBCYP2C19MAPTSMN1; SMN2
SCHEMBL11945032 0.81 ALDH1A1 (0.57) ALDH1A1POLBCYP3A4CYP2C19PPARG
SCHEMBL11945034 0.79 ALDH1A1 (0.55) ALDH1A1POLBCYP3A4CYP2C19PPARG
SCHEMBL11943926 0.79 POLB (0.56) ALDH1A1POLBCYP3A4CYP2C19PPARG
SCHEMBL11943929 0.78 ALDH1A1 (0.54) ALDH1A1POLBCYP3A4CYP2C19PPARG
SCHEMBL11943910 0.78 ALDH1A1 (0.57) ALDH1A1POLBCYP3A4CYP2C19PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA ALDH1A1 2437/4885POLB 1088/4885CYP3A4 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback